CD274 and neoplasm: The median survival time of patients with advanced HCC is only 1-2 years.20 In recent years, studies have suggested that the combination therapy with PD-L1 (atezolizumab) and vascular endothelial growth factor (VEGF) (bevacizumab) will bring in the very next future in patients with advanced HCC.21,22 However, because of the tumor heterogeneity, multidisciplinary treatments, including combination or sequential treatments, might be beneficial to advanced HCC patients.